These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 34576266)

  • 1. Personalized Medicine for TP53 Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia.
    Cluzeau T; Loschi M; Fenaux P; Komrokji R; Sallman DA
    Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34576266
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Eprenetapopt Plus Azacitidine in
    Cluzeau T; Sebert M; Rahmé R; Cuzzubbo S; Lehmann-Che J; Madelaine I; Peterlin P; Bève B; Attalah H; Chermat F; Miekoutima E; Rauzy OB; Recher C; Stamatoullas A; Willems L; Raffoux E; Berthon C; Quesnel B; Loschi M; Carpentier AF; Sallman DA; Komrokji R; Walter-Petrich A; Chevret S; Ades L; Fenaux P
    J Clin Oncol; 2021 May; 39(14):1575-1583. PubMed ID: 33600210
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Ball S; Loghavi S; Zeidan AM
    Leuk Lymphoma; 2023 Mar; 64(3):540-550. PubMed ID: 36323304
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Eprenetapopt (APR-246) and Azacitidine in
    Sallman DA; DeZern AE; Garcia-Manero G; Steensma DP; Roboz GJ; Sekeres MA; Cluzeau T; Sweet KL; McLemore A; McGraw KL; Puskas J; Zhang L; Yao J; Mo Q; Nardelli L; Al Ali NH; Padron E; Korbel G; Attar EC; Kantarjian HM; Lancet JE; Fenaux P; List AF; Komrokji RS
    J Clin Oncol; 2021 May; 39(14):1584-1594. PubMed ID: 33449813
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TP53-mutated acute myeloid leukemia and myelodysplastic syndrome: biology, treatment challenges, and upcoming approaches.
    Pereira MP; Herrity E; Kim DDH
    Ann Hematol; 2024 Apr; 103(4):1049-1067. PubMed ID: 37770618
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synergistic effects of PRIMA-1
    Maslah N; Salomao N; Drevon L; Verger E; Partouche N; Ly P; Aubin P; Naoui N; Schlageter MH; Bally C; Miekoutima E; Rahmé R; Lehmann-Che J; Ades L; Fenaux P; Cassinat B; Giraudier S
    Haematologica; 2020 Jun; 105(6):1539-1551. PubMed ID: 31488557
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Venetoclax and hypomethylating agents in TP53-mutated acute myeloid leukaemia.
    Aldoss I; Zhang J; Pillai R; Shouse G; Sanchez JF; Mei M; Nakamura R; Stein AS; Forman SJ; Marcucci G; Pullarkat V
    Br J Haematol; 2019 Oct; 187(2):e45-e48. PubMed ID: 31441045
    [No Abstract]   [Full Text] [Related]  

  • 8.
    Santini V; Stahl M; Sallman DA
    Am Soc Clin Oncol Educ Book; 2024 Jun; 44(3):e432650. PubMed ID: 38768424
    [No Abstract]   [Full Text] [Related]  

  • 9. Current State and Future Prospects of Diagnosis and Management of TP53-Mutated Myeloid Neoplasms.
    Venugopal S; Loghavi S
    Pathobiology; 2024; 91(1):45-54. PubMed ID: 37839402
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TP53-Mutated Myelodysplastic Syndrome and Acute Myeloid Leukemia: Biology, Current Therapy, and Future Directions.
    Daver NG; Maiti A; Kadia TM; Vyas P; Majeti R; Wei AH; Garcia-Manero G; Craddock C; Sallman DA; Kantarjian HM
    Cancer Discov; 2022 Nov; 12(11):2516-2529. PubMed ID: 36218325
    [TBL] [Abstract][Full Text] [Related]  

  • 11. What Are the Prospects for Treating TP53 Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia?
    Wang C; Sallman DA
    Cancer J; 2022 Jan-Feb 01; 28(1):51-61. PubMed ID: 35072374
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Biological and clinical significance of TP53 mutations in myelodysplastic syndrome and acute myeloid leukemia].
    Kojima K
    Rinsho Ketsueki; 2023; 64(9):955-961. PubMed ID: 37793871
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TP53-Mutated Myelodysplastic Syndrome and Acute Myeloid Leukemia: Current Guidelines, Therapies, and Future Considerations.
    DiGennaro J; Sallman DA
    Acta Haematol; 2024; 147(2):175-185. PubMed ID: 38052186
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Azacitidine combined with venetoclax alleviates AML-MR with TP53 mutation in SDS: a case report and literature review.
    Ma C; Lang H; Chen Y; Yang L; Wang C; Han L; Chen X; Ma W
    Anticancer Drugs; 2024 Jul; 35(6):548-555. PubMed ID: 38502829
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of p53 in myelodysplastic syndromes and acute myeloid leukemia: molecular aspects and clinical implications.
    Zhang L; McGraw KL; Sallman DA; List AF
    Leuk Lymphoma; 2017 Aug; 58(8):1777-1790. PubMed ID: 27967292
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes.
    Welch JS; Petti AA; Miller CA; Fronick CC; O'Laughlin M; Fulton RS; Wilson RK; Baty JD; Duncavage EJ; Tandon B; Lee YS; Wartman LD; Uy GL; Ghobadi A; Tomasson MH; Pusic I; Romee R; Fehniger TA; Stockerl-Goldstein KE; Vij R; Oh ST; Abboud CN; Cashen AF; Schroeder MA; Jacoby MA; Heath SE; Luber K; Janke MR; Hantel A; Khan N; Sukhanova MJ; Knoebel RW; Stock W; Graubert TA; Walter MJ; Westervelt P; Link DC; DiPersio JF; Ley TJ
    N Engl J Med; 2016 Nov; 375(21):2023-2036. PubMed ID: 27959731
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute myeloid leukemia or myelodysplastic syndrome with chromosome 17 abnormalities and long-term outcomes with or without hematopoietic stem cell transplantation.
    Britt A; Mohyuddin GR; McClune B; Singh A; Lin T; Ganguly S; Abhyankar S; Shune L; McGuirk J; Skikne B; Godwin A; Pessetto Z; Golem S; Divine C; Dias A
    Leuk Res; 2020 Aug; 95():106402. PubMed ID: 32590108
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clonal selection in therapy-related myelodysplastic syndromes and acute myeloid leukemia under azacitidine treatment.
    Calleja A; Yun S; Moreilhon C; Karsenti JM; Gastaud L; Mannone L; Komrokji R; Al Ali N; Dadone-Montaudie B; Robert G; Auberger P; Raynaud S; Sallman DA; Cluzeau T
    Eur J Haematol; 2020 May; 104(5):488-498. PubMed ID: 31990086
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of acute myeloid leukemia and myelodysplastic syndromes with TP53 aberrations.
    Dutta S; Moritz J; Pregartner G; Thallinger GG; Brandstätter I; Lind K; Rezania S; Lyssy F; Reinisch A; Zebisch A; Berghold A; Wölfler A; Sill H
    Ann Hematol; 2022 Apr; 101(4):837-846. PubMed ID: 35083527
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Eprenetapopt Plus Azacitidine After Allogeneic Hematopoietic Stem-Cell Transplantation for
    Mishra A; Tamari R; DeZern AE; Byrne MT; Gooptu M; Chen YB; Deeg HJ; Sallman D; Gallacher P; Wennborg A; Hickman DK; Attar EC; Fernandez HF
    J Clin Oncol; 2022 Dec; 40(34):3985-3993. PubMed ID: 35816664
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.